key: cord-0989474-4fyqjnwk authors: Broman, Niklas; Feuth, Thijs; Vuorinen, Tytti; Valtonen, Mika; Hohenthal, Ulla; Löyttyniemi, Eliisa; Hirvioja, Tiina; Jalava-Karvinen, Päivi; Marttila, Harri; Nordberg, Marika; Oksi, Jarmo title: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM – A prospective, randomized, single center, open label study date: 2022-03-05 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.02.027 sha: 4b167ec04af7b7f69b02fcad73a527e60262e508 doc_id: 989474 cord_uid: 4fyqjnwk OBJECTIVES: Severe COVID-19 is associated with an imbalanced immune response. We hypothesized that patients with enhanced inflammation, as demonstrated by increased levels of certain inflammatory biomarkers, would benefit from IL-6 blockage. METHODS: Hospitalized COVID-19 patients with hypoxemia and at least 2 out of 4 markedly elevated markers of inflammation (interleukin-6, CRP, ferritin and/or D-dimer) were randomized for tocilizumab plus standard of care or standard of care alone. Primary endpoint was clinical status at day 28 assessed using a 7-category ordinal scale and secondary endpoints included ICU admission, respiratory support, and duration of hospital admission. RESULTS: Clinical status at day 28 was significantly better in patients who received tocilizumab in addition to standard of care in comparison to those who received standard of care alone (p=0.037). By then, 93% (53/57) patients who received tocilizumab and 86% (25/29) of control patients were discharged from the hospital. 47% (27/57) of tocilizumab patients and 24% (7/29) of control patients had resumed normal daily activities. The median hospitalization was 9 (quartiles 7-12) days in the tocilizumab group and 12 (quartiles 9-15) days in the control group (p=0.014). CONCLUSION: In hospitalized COVID-19 patients with hypoxemia and elevated inflammation markers, administration of tocilizumab in addition to standard of care was associated with significantly better clinical recovery by day 28 and a shorter hospitalization compared to standard of care alone. Objectives 24 Severe COVID-19 is associated with an imbalanced immune response. We hypothesized that patients with 25 enhanced inflammation, as demonstrated by increased levels of certain inflammatory biomarkers, would 26 benefit from IL-6 blockage. 27 Hospitalized COVID-19 patients with hypoxemia and at least 2 out of 4 markedly elevated markers of 29 inflammation (interleukin-6, CRP, ferritin and/or D-dimer) were randomized for tocilizumab plus standard 30 of care or standard of care alone. Primary endpoint was clinical status at day 28 assessed using a 7-category 31 ordinal scale and secondary endpoints included ICU admission, respiratory support, and duration of 32 hospital admission. 33 Clinical status at day 28 was significantly better in patients who received tocilizumab in addition to standard 35 of care in comparison to those who received standard of care alone (p=0.037). By then, 93% (53/57) 36 patients who received tocilizumab and 86% (25/29) of control patients were discharged from the hospital. 37 47% (27/57) of tocilizumab patients and 24% (7/29) of control patients had resumed normal daily activities. 38 The median hospitalization was 9 (quartiles 7-12) days in the tocilizumab group and 12 (quartiles 9-15) days 39 in the control group (p=0.014). 40 In hospitalized COVID-19 patients with hypoxemia and elevated inflammation markers, administration of 42 Severe COVID-19 is associated with an imbalanced host response [1] . Indeed, high serum levels of 47 the groups with Wilcoxon rank sum test. Also, duration of hospitalization and ICU stay, length of oxygen 117 supplementation and IMV treatment were compared between the groups with Wilcoxon rank sum test. 118 Proportions (ICU, IMV, NIV) were compared using Fisher's exact test. P-values less than 0.05 (two-tailed) 119 were considered as statistically significant. CRP values (log transformed) were analyzed for the first seven 120 days from randomization by linear mixed models for repeated measurements. The model included group, 121 time as categorical within factor and also group by time interaction. 122 Statistical reporting was performed using SAS software, Version 9.4 of the SAS System for Windows (SAS 123 Institute Inc., Cary, NC, USA). 124 125 Laboratory procedures 126 The blood samples for biomarker level analysis were collected on admission and during the first few days in 127 hospital. IL-6 was available for analysis only during weekdays -CRP, ferritin, and D-dimer on any day. 128 Therefore, up to a 72-hours difference was allowed between baseline IL-6 measurement and study day 1. 129 All other inflammation markers were taken at the day of randomization. Serum CRP, plasma ferritin and D-130 dimer levels were analyzed at the Department of Chemistry, according to standard procedures, and plasma 131 IL-6 levels using a commercial, sandwich enzyme immunoassay (Human Interleukin- The consort flowchart is presented in Figure 1 . Median National Early Warning Score (NEWS) at 145 randomization was 6, with 1.2% (1/86) patients receiving IMV at randomization. 5.3% (3/57) of patients in 146 TCZ group and 6.9% (2/29) patients in SoC group did not receive supplemental oxygen or any other 147 respiratory support at randomization. All patients in SoC group and 91% (52/57) patients in TCZ group were 148 receiving glucocorticoids, almost all of them oral dexamethasone 6mg daily, at randomization. None of the 149 subjects were fully and only two partially vaccinated by the time of randomization. There were no clinically 150 meaningful differences in the baseline data between groups ( Table 2) . 151 152 Clinical status at day 28, as measured by the 7-category scale, was significantly better in patients who 154 received TCZ in comparison to those who received SoC (p=0.037). By then, 93% (53/57) of patients in the 155 TCZ group and 86% (25/29) in the SoC group were discharged from the hospital. 47% (27/57) of patients in 156 the TCZ group and 24% (7/29) of patients in the SoC group had resumed normal daily activities. 157 One patient in the TCZ group and none in the SoC group died. This 79-year-old patient with atrial fibrillation 158 and type 2 diabetes as underlying conditions had a do-not-resuscitate-decision before randomization 159 according to her own request. She died on day 27 without evidence of secondary infections or 160 thromboembolic complications. Autopsy was not performed. 161 The primary endpoint is presented in Figure 2 . The median duration of hospital admission was 9 (quartiles 7-12) days in patients receiving TCZ and 12 165 (quartiles 9-15) days in the control group (p=0.014). Incidence of ICU treatment was 8.0% (4/50) in the TCZ 166 group and 16.0 % (4/25) in the SoC group (p=0.43) and the median duration of ICU stay 6 (quartiles 4-12) 167 days and 5 (quartiles 3.5-24) days, respectively. The incidence of IMV treatment was 8.8% (5/57) in TCZ 168 group and 10.8% (3/28) in SoC group (ns). None of the patients received ECMO or renal replacement 169 therapy. Median duration of respiratory support other than supplemental oxygen alone during treatment 170 period in Turku University Hospital among all patients (n=86) was 5 (quartiles 4-10) days in TCZ group and 4 171 (quartiles 3-7) days in SoC group. Median duration of any oxygen supply was 6 (quartiles 3-8) days in TCZ 172 group and 6.5 (quartiles 3.5-10) days in SoC group during admission. 24% (21/86) of patients were referred 173 to a local hospital or health center for continuation of inpatient treatment. In those patients, data on 174 supplemental oxygen was only available from the primary center. Secondary outcomes are summarized in 175 Table 3 . In our randomized study, patients receiving TCZ in addition to SoC displayed significantly better clinical 190 recovery by day 28 compared to patients receiving SoC alone. Furthermore, administration of TCZ was 191 associated with shorter hospitalization. CRP values declined rapidly and consistently after administration of 192 TCZ. 193 Previous randomized trials indicate that TCZ improves survival, reduces incidence of IMV and may lead to 194 shorter admission in hospitalized COVID-19 patients [12] [13] [14] . In the WHO meta-analysis, TCZ was associated 195 with significant reduction in mortality (summary odds ratio 0.83, 95% confidence interval 0.74-0.92), which 196 was even stronger in patients receiving corticosteroids (summary odds ratio 0.77, 95% confidence interval 197 0.68-0.87) [12] . In another meta-analysis of randomized studies on TCZ use, the 1-month mortality rate was 198 24.5% in the TCZ group and 29.1% in the control group [15] . Importantly, administration of TCZ was not 199 associated with a higher risk of secondary infections or other adverse events [12, 15, 16] . 200 In the COVACTA-trial, which used nearly identical primary study endpoints as we did, clinical status at day 201 28 was similar between TCZ and placebo groups [13] . However, symptom duration before inclusion and 202 levels of CRP and IL-6 varied much more than in our study [13] . The more homogenous selection of patients 203 might explain why clinical benefit was detected in the primary endpoint of our study. Our study has several limitations. As compromised health care services and shortness of clinical staff was 231 anticipated early in the pandemic, we decided to perform this study without placebo nor blinding despite 232 the risk of bias. Of screened patients, only 33% were included. The high screening failure was partly caused 233 by the screening procedure, as all hospitalized COVID-19 patients were screened for eligibility to the study. In conclusion, our study shows that addition of TCZ to SoC in hospitalized patients is associated with ≥85 years, n (%) 1 (1.75) 0 (0) Body mass index, mean value ± SD, kg/m 2 33.15 ± 6.4 32.8 ± 13.7 33.02 ± 6.9 Illness severity by National Early Warning Score J o u r n a l P r e -p r o o f ---27 47 7 24 2 ----26 46 18 62 3 9 16 2 7 2 4 --4 41 72 23 79 --2 7 5 7 12 3 10 ----6 --1 3 1 2 2 7 7 ----1 Imbalanced host response to 333 SARS-CoV-2 drives development of COVID-19 IL-6 and other biomarkers 337 as predictors of severity in COVID-19 The role of C-reactive protein as a 340 prognostic marker in COVID-19 Serum ferritin is an independent risk 343 factor for acute respiratory distress syndrome in COVID-19 Immunothrombotic 347 dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy Pulmonary vascular 350 endothelialitis, thrombosis, and angiogenesis in covid-19 Endothelial cell 353 infection and endotheliitis in COVID-19 D-dimer levels on admission to predict in-hospital mortality 356 in patients with Covid-19 Immunity, endothelial injury and 359 complement-induced coagulopathy in COVID-19 Interleukin-362 6 receptor antagonists in critically ill patients with Covid-19 Tocilizumab in patients hospitalized with 365 covid-19 pneumonia Association between administration of IL-6 antagonists and 368 mortality among patients hospitalized for COVID-19: A meta-analysis Tocilizumab in Hospitalized Patients 371 with Severe Covid-19 Pneumonia Tocilizumab in patients admitted to hospital with COVID-19 374 (RECOVERY): a randomised, controlled, open-label, platform trial HNF Hospital 377 tocilizumab multidisciplinary team. Systematic Review and Subgroup Meta-analysis of Randomized Trials Determine Tocilizumab's Place in COVID-19 Pneumonia Efficacy and safety of tocilizumab 381 in COVID-19 patients: a living systematic review and meta-analysis Effect of anti-384 interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, 385 randomised, controlled trial Prognostic and Predictive 388 Biomarkers in Patients With Coronavirus Disease Online ahead of print Covid's color line -infectious disease, inequity, and racial justice Factors associated with 394 COVID-19-related death using OpenSAFELY